The team used human stem cells to create embryo-like structures dubbed “hematoids” that mirror some features of early human ...

With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years. Some will even get a chance ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.